PurposeTreatment with programmed cell death-1 or programmed death ligand 1 (PD-(L) 1)
inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, …

Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …

PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments.
Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), …

Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied
mostly in small cohorts without sufficient follow-up to determine its influence on overall …

… W. Victoria Lai: Formal analysis and writing–original draft, review, and editing. Elena
Pentsova: Formal analysis and writing–original draft, review, and editing. Adrienne Boire: Formal …

Access to clinically relevant small cell lung cancer (SCLC) tissue is limited because surgical
resection is rare in metastatic SCLC. Patient-derived xenografts (PDX) and circulating tumor …

RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts
in estrogen receptor-positive (ER + ) breast cancer, but their role in disease pathogenesis …

Introduction POU2F3 is a recent marker of a small cell lung carcinoma (SCLC) subtype related
to chemosensory tuft cells (SCLC-P). The characteristics of SCLC-P have not been fully …

Purpose: RB1 mutations and loss of retinoblastoma (Rb) expression represent consistent
but not entirely invariable hallmarks of small cell lung cancer (SCLC). The prevalence and …